CMaT -Research Services
The goal of CMaT is to transform the production of cell-based therapeutics into a large-scale, low-cost, reproducible, and high-quality engineered manufacturing process for broad industry and clinical use. Specifially, three Engineered Systems (Test-Beds) are envisioned: Mesenchymal Stem/Stromal Cells (MSCs) to repair, regenerate, and restore diseased tissues and organs. T cell immunotherapies to cure cancer. Induced Pluripotent Stem Cell-derived cardiac cells (iPSC-CM) to treat heart diseases. In each of these Test-Beds, CMaT will focus on three, synergistic technical innovation Thrusts: cell-omics for biomarker discovery (Thrust 1); rapid and reliable assessment of cell quality, i.e. potency and safety (Thrust 2); and process and systems engineering for scale-up or scale-out manufacturing (Thrust 3).
CMaT’s overall research plan and its impact on industry and workforce is shown below. This strategic plan is structured around a broad stakeholder-driven ecosystem with three inter-dependent and convergent Thrusts, and three industry-relevant Test-Beds (Engineered Systems) that are integrated and cross-cutting across all three Thrust areas. As shown, CMaT will have tremendous impact in strengthening the nascent industry.
